Co-Inventors
Chao, Cara
Kwong, Peter
Chauang, Gwo-yu
Mascola, John
Kong, Wing-pui
Zhang, Baoshan
Zhou, Tongqing
Li, Ou
Yang, Yongping
Therapeutic Areas
Metabolic Disease
Geriatrics
Endocrinology
Cardiology
Research Products
Plasmids/Vectors
Human Cell Lines
Antibodies
The technology involves the development of novel PCSK9 immunogens that are specifically designed to eliminate sequence overlap with human proteins, thereby reducing potential self-reactivity and immunogenicity issues. By selectively grafting epitope residues from non-human PCSK9 or structurally similar sequences onto the epitope-scaffold, these immunogens can induce an immune response against the PCSK9 enzyme without triggering a significant reaction against the body’s own proteins. This innovative approach has led to the creation of a new PCSK9 immunogen named HIT01, which has demonstrated a significant reduction in low-density lipoprotein (LDL) and overall cholesterol levels in immunized mice. The PCSK9 immunogens offer a promising new avenue for creating vaccines or treatments to manage hyperlipidemia and prevent heart disease.
Commercial Applications
The novel PCSK9 immunogens represent a transformative approach with broad applications across various fields of medicine. Primarily, they can be utilized to develop vaccines for the prevention and long-term management of hyperlipidemia and associated cardiovascular diseases, reducing the dependency on daily medications and improving patient compliance. Beyond cardiovascular health, these immunogens could be adapted for therapeutic interventions in metabolic disorders where cholesterol regulation is disrupted. The technology could also be employed in the design of precision medicine strategies, where individual patient’s immunogenic profiles are considered to optimize therapeutic efficacy. Furthermore, the foundational methodology of minimizing human protein sequence overlap in immunogens could be extended to other therapeutic targets, revolutionizing the way we design and implement immunotherapies for a range of autoimmune and inflammatory diseases.
Competitive Advantages
The developed PCSK9 immunogens exhibit competitive advantages over existing therapies for hyperlipidemia by minimizing immune system reactions against self-proteins, a common drawback of current treatments. This is achieved through the innovative design of epitopes that eliminate sequence homology with human proteins, which in turn reduces potential adverse immunogenicity. When compared to existing monoclonal antibody therapies that target PCSK9, this approach offers a potentially safer and more sustainable long-term treatment option by harnessing the body’s own immune system rather than relying on regular external administration of therapeutic antibodies. Additionally, the technology's adaptability to various delivery systems, such as nanoparticles or carrier constructs, not only enhances the immunogen's efficacy but also provides flexibility in formulation and administration methods, positioning it as a versatile and less invasive alternative in the hyperlipidemia therapeutic landscape.
